CC-4047

What CC-4047 Means in Everyday Medical Language

CC-4047 is the scientific code name for a drug more commonly known as pomalidomide or by its brand name Pomalyst. It is a medication used mainly to treat adults with certain cancers, especially multiple myeloma—a cancer of plasma cells in the bone marrow—and Kaposi sarcoma, a cancer affecting the skin and other tissues. Pomalidomide belongs to a group of drugs called immunomodulating agents, which help the immune system recognize and attack cancer cells. It may also block the growth of new blood vessels that tumors need to grow.

Why CC-4047 Can Matter in Cancer Care

Pomalidomide offers an important treatment option for patients whose cancer has not responded to other therapies. For example, in multiple myeloma, it is often used when the disease worsens despite prior treatments. It is usually given with another drug called dexamethasone. For Kaposi sarcoma, pomalidomide can be used in adults with or without HIV infection, especially when other treatments have not worked well. Because it affects the immune system and blood vessel growth, pomalidomide requires careful monitoring and is only available through a special safety program called Pomalyst REMS, which helps manage risks and ensures safe use.

What Patients Might See or Hear About CC-4047

Patients may come across the terms CC-4047, pomalidomide, or Pomalyst during discussions about treatment options, clinical trials, or medication plans. It may appear on prescription labels, treatment summaries, or educational materials. Hearing about this drug does not mean it is the right treatment for every patient. Its use depends on the type and stage of cancer, previous treatments, and overall health. Patients should ask their healthcare team about how pomalidomide works, possible side effects, and what monitoring will be needed during treatment.

Safety and Special Use Considerations

Because pomalidomide is related to thalidomide, a drug known for causing serious birth defects, it is critical to follow strict safety guidelines. Pomalidomide is only available through the Pomalyst REMS program, which includes measures to prevent pregnancy during treatment and to monitor for side effects. Patients should discuss pregnancy risks and contraception with their healthcare providers. This special program reflects the importance of careful use to protect patients and others.

Understanding What CC-4047 Does Not Automatically Mean

Seeing the name CC-4047 or pomalidomide does not mean a patient will receive this drug or that it is suitable for all cancers. Its approved uses are currently limited to certain cases of multiple myeloma and Kaposi sarcoma. While it is being studied for other cancers, these uses are not yet established. Doctors consider many factors before recommending pomalidomide, including how the cancer has responded to earlier treatments and the patient’s ability to tolerate the drug.

Next Steps for Patients and Caregivers

If you hear about CC-4047 or pomalidomide, it can help to think of it as a medicine designed to support the immune system in fighting certain cancers and to slow tumor growth. It is one of several options that may be considered when other treatments have not been effective. Always talk with your doctor or nurse about what this drug means for your specific situation, including benefits, risks, and how it fits into your overall care. Remember, this information is educational and not a substitute for medical advice. Your healthcare team is the best source for guidance tailored to your health and treatment needs.